

# **An Indirect Comparison of Polihexanide 0.08% Versus Currently Used Treatments for Acanthamoeba Keratitis**



M De Francesco<sup>1</sup>, E Spaepen<sup>2</sup>, DH Bodicoat<sup>2</sup>, C Galeone<sup>3</sup>, L Cardosi<sup>4</sup>, V Papa<sup>4</sup>

<sup>1</sup>HEOR Value Hub, VLI (BE) <sup>2</sup>HEOR Value Hub, Brussels (BE) <sup>3</sup> Bicocca-Applied Statistics Center (B-ASC), Milan (IT) <sup>4</sup>SIFI S.p.A., Catania (IT)

## Aim

The objective of this study was to compare the efficacy of polihexanide 0.08% versus currently used off-label anti-amoebic therapies in patients with acanthamoeba keratitis (AK).

## Background

- AK is a rare, potentially devastating, microbial keratitis.<sup>1</sup>
- Approximately 90% of AK cases occur in contact lens wearers.<sup>2-5</sup>
- AK is associated with pain, photophobia, blurred vision, and tearing.<sup>1</sup>
- Akantior (polihexanide 0.08%) has recently become the first EMA-approved medicinal product for treating AK. There are no other approved treatments in any country.<sup>6</sup>

## Results

- The CRR before and after weighting are shown in Table 1.
- The baseline characteristics and effective sample sizes in the weighted populations suggested that the indirect treatment comparison had successfully aligned the analysis populations.
- The absolute differences in CRR between polihexanide 0.08% and comparator treatments are shown in Figure 1.
- There are also currently no clinical guidelines for the management of AK.<sup>6</sup>
- In all comparisons, the CRR was significantly higher with polihexanide 0.08% than the comparator treatment, with differences ranging from 24% to 45% higher.

### Methods

#### **Data Sources and Comparator Treatments**

- A propensity score analysis (PSA) was conducted using individual patient data (IPD) from:
  - **Polihexanide 0.08%:** A phase 3 trial 043/SI (NCT03274895)
  - **Current therapies:** The largest retrospective study in people with AK (Papa 2020<sup>7</sup>)
- For the Papa 2020 data, three populations were analysed:
  - Whole study population, referred to as 'any initial pharmacological treatment'
  - Patients treated with **polihexanide 0.02% plus a diamidine 0.1%**
  - Patients treated with chlorhexidine with or without propamidine 0.1%


#### **Endpoint of Interest**

- Difference in clinical resolution rate (CRR)
- Defined as cure without no surgery within 12 months of treatment
- Discontinuations from baseline therapy were considered as 'failure'

#### **PSA Approach**

- A PSA with overlap weights normalised to account for the study sample size
- IPD were reweighted to balance study populations for key prognostic factors and/or treatment effect modifiers: age; gender; AK disease stage; prior use of corticosteroids;

## **Figure 1: PSA Results**



prior use of antivirals; delay in starting treatment from diagnosis.

- The calculated estimate was based on the average treatment effect
- CRR was assessed using logistic regression methods to estimate the absolute difference between treatments and the corresponding 95% confidence interval (CI)

## Table 1: Summary of Cure Rates

Study	Рара	Papa 2020		NCT03274895	
Weighting	Unadjusted	Adjusted	Unadjusted	Adjusted	
Arm	Any initial pharma	Any initial pharmacological treatment		Polihexanide 0.08%	
Na	227	174.0	66	64.8	
% (95% CI) cured without surgery	43.6 (37.1, 50.3)	48.3 (41.8, 54.8)	84.8 (73.9 <i>,</i> 92.5)	84.7 (76.1, 93.4)	
Arm	Chlorhexidine with or	Chlorhexidine with or without propamidine		Polihexanide 0.08%	
Na	35	25.7	66	41.9	
% (95% CI) cured without surgery	40.0 (23.9 <i>,</i> 57.9)	46.4 (29.9, 63.0)	84.8 (73.9 <i>,</i> 92.5)	83.3 (74.3, 92.3)	
Arm	Polihexanide 0.02	Polihexanide 0.02% plus a diamidine		Polihexanide 0.08%	
Na	111	97.5	66	62.5	
% (95% CI) cured without surgery	55.0 (45.2 <i>,</i> 64.4)	60.9 (51.9 <i>,</i> 70.0)	84.8 (73.9 <i>,</i> 92.5)	85.1 (76.6, 93.7)	

<sup>A</sup>N in the 'Adjusted' column is the Effective Sample Size estimated from the weighted data.

#### Conclusion

These analyses suggest an improved efficacy with polihexanide 0.08% compared with currently used anti-amoebic therapies in achieving clinical resolution with no surgery in AK.

#### **References:**

1. Kaufman AR, Tu EY. Advances in the management of Acanthamoeba keratitis: A review of the literature and synthesized algorithmic approach. Ocul Surf. Jul 2022;25:26-36. doi:10.1016/j.jtos.2022.04.003

- 2. Lorenzo-Morales J, Khan NA, Walochnik J. An update on Acanthamoeba keratitis: diagnosis, pathogenesis and treatment. Parasite. 2015;22:10. doi:10.1051/parasite/2015010
- 3. Radford CF, Minassian DC, Dart JK. Acanthamoeba keratitis in England and Wales: incidence, outcome, and risk factors. Br J Ophthalmol. May 2002;86(5):536-42. doi:10.1136/bjo.86.5.536
- 4. Szentmáry N, Daas L, Shi L, et al. Acanthamoeba keratitis Clinical signs, differential diagnosis and treatment. Journal of Current Ophthalmology. 2019;31(1):16-23.
- 5. Duguid IG, Dart JK, Morlet N, et al. Outcome of acanthamoeba keratitis treated with polyhexamethyl biguanide and propamidine. Ophthalmology. Oct 1997;104(10):1587-92. doi:10.1016/s0161-6420(97)30092-x
- 6. Büchele MLC, Nunes BF, Filippin-Monteiro FB, Caumo KS. Diagnosis and treatment of Acanthamoeba Keratitis: A scoping review demonstrating unfavorable outcomes. Cont Lens Anterior Eye. Apr 26 2023:101844. doi:10.1016/j.clae.2023.101844
- 7. Papa V, Rama P, Radford C, Minassian DC, Dart JKG. Acanthamoeba keratitis therapy: time to cure and visual outcome analysis for different antiamoebic therapies in 227 cases. Br J Ophthalmol. 2020;104(4):575-81.

Funding: This study was funded by SIFI S.p.A.